Collectively, these findings suggest that overexpression of HIF‐2α in RCC may contribute to suboptimal clinical responses to immunotherapy, with inhibiting HIF‐2α expression representing a promising strategy to enhance the efficacy of immunotherapy in RCC patients. The gene discussed is EPAS1; the disease is renal cell carcinoma.